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Gonadotropin  releasing  hormone  (GnRH)  agonists  are  used  in  the  treatment  of  hormone-
dependent  gynaecological  tumours.
The  authors  report  the  case  of  a  patient  treated  for  MRI-diagnosed  and  monitored,
multi-recurrent  aggressive  angiomyxoma,  a  rare  disease  that  regressed  under  Enantone®
(Leuprorelin).
Case report
In  2002,  a  young  36-year-old  woman  underwent  surgery  for  a  3  cm  by  8  cm  tumour  on  the
recto-vaginal  septum,  responsible  for  invalidating  pelvic  pain  (Fig.  1a  and  b).  The  excision
was  complete  and  the  diagnosis  was  that  of  atypical  leiomyoma.
Five  years  later,  in  January  2007,  the  patient  presented  a  recurrence  of  the  symptoma-
tology.  The  MRI  detected  a  local  tumour  of  11  cm  located  at  the  site  of  the  initial  excision
(Fig.  1c  and  d).  The  patient  again  underwent  surgery  (Fig.  2a).  The  anatomopathological
diagnosis  was  changed  to  that  of  aggressive  angiomyxoma  (Fig.  2b  and  c).  The  histology
revealed  the  presence  of  tumour  cells  expressing  œstrogen  and  progesterone  receptors
(Fig.  2d).
In  June  2008,  18  months  after  the  second  intervention,  another  local  recurrence  was
noted  (Fig.  3a  and  b).  In  view  of  the  hormone-dependent  nature  detected  in  the  previous
histology,  a  decision  was  made  to  avoid  another  intervention  and  start  treatment  with
Enantone® (a  GnRH  agonist).  The  lesion  regressed  6  months  after  beginning  treatment.
Only  a  ﬁbrous  strip  was  visible  in  the  imaging  (Fig.  3c  and  d).
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Figure 1. a, b: MRI of the initial lesion, 2002; a: axial plane; b: sagittal plane weighted sequence T2: tumoral lesion (arrow) of the
recto-vaginal space, 48 × 22 × 20 mm, heterogeneous in moderate hypersignal T2; c, d: MRI of the ﬁrst tumoral recurrence, 2007; c: axial
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Eighteen  months  later,  the  patient  suspended  the  treat-
ent  due  to  the  poorly  tolerated  adverse  effects.  The  lesion
eturned  6  months  after  the  suspension  of  the  treatment
Fig.  4a  and  b).  It  regressed  as  soon  as  the  treatment  was
estored  (Fig.  4c  and  d).  The  patient  is  currently  completely
tabilised  by  this  treatment  and  a  distant  location  has  not
een  observed.
iscussion
ggressive  angiomyxoma  is  difﬁcult  to  diagnose  because  it
s  rare  (described  in  1983,  about  250  cases  in  the  litera-
ure),  although  knowledge  of  its  radiological  semiology  [1],
he  predisposition  and  its  natural  history  should  call  it  to
ind.
This  myxoid  mesenchymateous  lesion  of  the  perineal
elvic  region  is  locally  aggressive  although  benign  (only  two
ases  of  secondary  locations  have  been  reported).  Ninety
ercent  of  the  cases  involve  young  women  in  their  4th
ecade.  Several  cases  have  been  described  in  men,  with
crotal  and  inguinal  locations,  and  a  peak  at  60  to  70  years.The  clinic  picture  is  aspeciﬁc,  characterised  by  the  often
symptomatic,  slow  growth  of  a  soft  and  mobile  mass  in
he  paravaginal  or  pararectal  space.  Initially,  the  lesion  is
rroneously  taken  for  a  leiomyoma  or  a  parasitic  myoma  [2].
(
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h-vaginal space (arrow) extending along the right lateral wall of the
s muscle is no longer visible.
t  differs  from  diffuse  peritoneal  leiomyomatosis  due  to
ts  extra-peritoneal  location,  or  a  rectal  GIST,  a  very  rare
ocation  and  the  existence  of  a  healthy  wall  and  a  bor-
er  of  fat  separating  the  lesion  from  the  rectal  muscularis.
etrorectal  tumours  are  not  found  in  this  place  and  speciﬁ-
ally  present  a  liquid  or  fatty  sheath  although  heterogeneous
3].
In  MRI,  the  lesion  appears  well  limited  in  hypersignal  T2,
yposignal  T1,  taking  the  contrast  heterogenically.  The  typ-
cally  paravaginal  or  pararectal  location  and  its  very  speciﬁc
ocal  extension  indicate  this  diagnosis  and  allow  it  to  be
istinguished  from  retro-rectal  tumours.
Macroscopically,  the  lesion  appears  as  a  soft,  gelatinous,
on-encapsulated  mass  without  distinct  limits,  with  a  poly-
obed  outline,  inﬁltrating  the  adjacent  soft  tissue.
In  histology,  this  lesion  consists  of  connective  cells  dis-
ersed  on  a  myxoid  and  collagen  background  with  rich
ascularisation.  There  is  no  cytonuclear  atypy  or  mito-
is.  The  tumour  cells  express  the  hormone  receptors
o  œstrogens  and  progesterone,  thereby  conﬁrming  the
ormone-dependent  nature  of  this  lesion  [4].
Therefore,  the  use  of  GnRH  agonists,  such  as  leuprorelin
Enantone®),  is  justiﬁed  to  inhibit  the  pituitary  secretion
f  gonadotropins  (FSH/LH).  Leuprorelin  ﬁxes  on  the  same
iaison  site  as  endogenous  GnRH  on  its  receptor,  but  with  a
igher  afﬁnity  and  an  inhibiting  effect.
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Figure 2. Macroscopy and histology. a: macroscopic sample of the recurrence in 2007; b: HES, × 40, HES staining: proliferation or small
fusiform or star-shaped cells, without cytonuclear atypia (arrow) dispersed on a myxoid background (solid arrow) enclosing several capillary
structures with a thin wall; c: HES, × 40, immunohistochemistry: rare smooth residual muscle cells stained by anti-smooth muscle antibodies
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t(arrow). Absence of staining of the tumour cells; d: × 40, immunohist
(arrow).
In  the  case  of  our  patient,  the  resulting  state  of  hypog-
onadism  ends  by  a  spectacular  reduction  in  the  size  of  the
tumour,  although  complicated  by  the  classic  adverse  effects
of  menopause  (hot  ﬂashes,  sweating  at  night,  mood  disor-
ders).
The  speciﬁc  diagnosis  of  this  tumour  and  its  hormone-
dependent  nature  enable  medical  treatment  and  avoid
mutilating  surgery,  that  is,  abdominal-perineal  amputation
in  young  women,  without  any  effect  on  the  number  of
recurrences  [5,6].  The  several  cases  in  the  literature  also
reveal  a  satisfactory  response  in  carcinological  terms  under
long-term  treatment  [7,8].
p
m
tmistry: coloration of most of the nuclei by anti-œstrogen antibodies
The  originality  of  this  case  lies  in  the  efﬁcacy  of
nantone® with  regression  in  the  size  of  the  tumour  as  of
 months  of  treatment.  The  premature  suspension  (after  18
onths)  of  this  treatment,  due  to  the  adverse  effects,  very
uickly  led  to  a  tumour  recurrence  that  regressed  as  soon
s  the  treatment  was  resumed.  This  also  demonstrates  the
irect  response  and  on/off  effect  of  hormone  therapy  on
his  locally  aggressive  lesion.Due  to  the  hormone-dependence  of  this  lesion,  the
atient  will  therefore  continue  treatment  until  physiological
enopause  [9], associated  with  monitoring  and  the  preven-
ive  treatment  of  osteoporosis.
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Figure 3. a, b: MRI of the second recurrence, June 2008; a: axial plane T1 after injection and saturation of the fat; b: frontal plane T2:
appearance of two tissue nodules on the ﬁbrous scar, 6 mm and 14 mm (arrows), presenting the same characteristics as the initial lesion.
Establishment of a hormone treatment (Enantone®); c, d: MRI carried out 6 months after beginning the hormone treatment, December
2008; c: axial plane T1 after injection and saturation of the fat; d: frontal plane T2: regression of the tumour taking on the appearance of
a ﬁbrous strip (tip of the arrow).
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Figure 4. a, b: MRI of the third recurrence, January 2011, 6 months after the suspension of Enantone®; a: axial plane T1 after injection
and saturation of the fat; b: frontal plane T2: nodular lesion (arrows) with homogenous and intense contrast, in hypersignal T2, opposite the
right anterolateral edge of the anal canal and lower rectum, measuring 25 × 34 × 52 mm, in contact with the posterior wall of the vagina.
Resumption of the hormone therapy; c, d: MRI carried out 1 year after the third recurrence and resumption of the hormone therapy, January
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[2012; c: axial plane T1 after injection and saturation by the fat; d: 
arrow). The patient is still receiving hormone therapy.
Conclusion
Aggressive  angiomyxoma  is  a  rare  disease  that  the  radiolo-
gist  should  keep  in  mind  when  confronted  with  a  soft  and
mobile,  often  painful,  recurrent  tumour  of  the  paravaginal
or  pararectal  space  in  a  young  woman.  Treatment  with  a
GnRH  agonist  avoids  mutilating  surgery  that  does  not  pre-
vent  recurrences.
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